Project Grant K23AI187709
Award Date
12/10/24
Completion Date
11/30/29
Dollars Obligated
$202K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the sirtuin-dependent regulation of tuberculosis (TB) and HIV interactions in macrophages. The total award amount is $1,297,775.00 over a 5-year period from August 1, 2024 to July 31, 2029. The primary objectives are to: 1) analyze the impact of early TB and HIV infection on sirtuin gene and protein...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to identify and adapt an intervention to address common mental disorders (CMDs) among people being treated for tuberculosis (TB) in Uganda. The total award amount is $134,811 over a 5-year period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) examine the relationship between CMDs and TB...
This Project Grant award, totaling $559,341, was provided by the Fogarty International Center (FIC), part of the U.S. Department of Health and Human Services National Institutes of Health, under the International Research and Research Training program (CFDA 93.989). The award supports research to improve detection and treatment of tuberculosis (TB) in children under five years old in Malawi. Specifically, the project will: Evaluate the accuracy of new non-invasive TB diagnostic strategies...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $193,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on August 20, 2024. The award will fund a 5-year research project titled "The Relationship Between HIV Exposure, Contact Networks, and TB in Children Under 5 Years Old." As part of this project, BMC will collaborate with Stellenbosch University in South Africa, which...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $766,877 randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) for linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The primary objective is to determine if TDM can prevent premature discontinuation of linezolid, a critical drug for treating RR-TB. The...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...